Interesting day here today Dibs......that run of trades is very unusual
Two sizeable late reported buys. This could easily treble or quadruple and still barely scratch the surface of Lupuzor potential.
Been a few false dawns here but is IMM showing signs of life? No tick up yet BUT a few buys starting to come in and offer price creeping up. Not trading this, its definitely an ISA type investment, but any sign of upcoming news would be welcome.
woodford patient trust
According to wealth website - the new patient trust has invested in sphere mkt cap 12mn he reveals that he has about 29 more investments to hand expect the directors of immupharma to be issuing shares for modest dilution but for a long term holder and the phase 3 trials to be announced Immupharma with its valuable advance approval for USA is ideally placed for this fund and they have a 12 month trial If the directors dont access thisfunding they should bid for the part of the company they do not already own along with other large shareholders and take the company private
So much for news flow
Dibs agreed...First time poster here although have held and read posts for three years...must say that even my patience is beginning to wear thin now....had stock email reply from Lisa last week. Anyone else tried to get a differing response? Would imm have to rns when trial started or can they update when in full flow?
New US patent application published today at: http://www.freepatentsonline.com/20150111835.pdf
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.